New study investigates Wegovy's risks for pregnant women
NCT ID NCT05503927
First seen Jan 16, 2026 · Last updated May 10, 2026 · Updated 13 times
Summary
This study uses insurance records to compare pregnancy outcomes in women who took Wegovy (semaglutide) during pregnancy versus those who did not. Researchers will look at birth defects, low birth weight, and other health issues in mothers and babies. The goal is to help patients and doctors make informed decisions about using Wegovy while pregnant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novo Nordisk Investigational Site
Princeton, New Jersey, 08540, United States
Conditions
Explore the condition pages connected to this study.